Latest news about Innova Captab
Innova Captab
914.70
+44.65(+5.13%)
Company Performance:
View Company Insights1D+5.13%
1M+4.45%
6M+36.82%
1Y+3.24%
5Y+68.95%
More news about Innova Captab
15May 26
Innova Captab FY26 Earnings Call: Revenue Hits ₹1,630 Crores, Jammu Nears EBITDA Breakeven
Innova Captab delivered its highest-ever FY26 consolidated revenue of ₹1,630 crores (up 31% YoY), with CDMO revenue at ₹1,133 crores and Branded Generics at ₹497 crores. The Jammu facility achieved ~₹300 crores in its first full year, nearing EBITDA breakeven, while Baddi expansion capex of ₹150–₹170 crores is planned for FY27–FY28. Management guided 20%-plus revenue growth for FY27 with EBITDA and PAT growth expected to outpace revenue growth.
05May 26
Innova Captab Promoters Declare No Encumbrance on Shares for FY26 Under SEBI Takeover Regulations
Innova Captab Limited's promoters filed a declaration on April 3, 2026, under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, confirming no encumbrance on promoter equity shares for the financial year ended March 31, 2026. The declaration, signed by promoter Vinay Lohariwala, was submitted to BSE Limited and the National Stock Exchange of India Limited. The filing lists five individuals — including two promoters and three promoter group members — as part of the promoter and PAC group.
01May 26
Innova Captab Limited Schedules Earnings Call for Q4 FY26 Results Discussion on May 8, 2026
Innova Captab Limited has officially announced its Q4 and FY26 earnings call scheduled for May 8, 2026 at 11:00 AM IST. The virtual meeting will be conducted by key leadership including Managing Director Vinay Lohariwala and CFO Lokesh Bhasin to discuss audited financial results with analysts and institutional investors, coordinated by Strategic Growth Advisors.
14Apr 26
Innova Captab Limited Receives CARE A; Positive Rating Reaffirmation for Enhanced Bank Facilities
CARE Ratings Limited reaffirmed Innova Captab Limited's credit ratings on April 14, 2026, maintaining CARE A; Positive for long term bank facilities of ₹426.72 crore (enhanced from ₹389.38 crore) and CARE A1 for short term facilities of ₹40.00 crore (enhanced from ₹20.00 crore). The rating review was based on the company's operational and financial performance for FY25 and 9MFY26, with the company maintaining strong banking relationships across multiple institutions including HDFC Bank, State Bank of India, and Yes Bank.
14Apr 26
Innova Captab Limited GST Proceedings Concluded with No Liability
Innova Captab Limited has successfully concluded GST proceedings with the adjudicating authority dropping a proposed demand of ₹15,81,37,255.40 and all penal proceedings. The authority found that matters raised in the October 2025 show cause notice were not legally sustainable, resulting in no liability for the company.
08Apr 26
Innova Captab Limited Submits Q4FY26 Compliance Certificate to Stock Exchanges
Innova Captab Limited filed its Q4FY26 compliance certificate with BSE and NSE on April 08, 2026, pursuant to SEBI Regulation 74(5). The certificate from KFin Technologies Limited confirms no dematerialization or rematerialization requests were received during January-March 2026 period. The company trades as INNOVACAP on both exchanges with BSE scrip code 544067.
02Apr 26
Vistra ITCL Acquires 3.28% Stake in Innova Captab Limited Through Non-Disposal Undertaking
Vistra ITCL (India) Limited has acquired a 3.28% stake in Innova Captab Limited through a non-disposal undertaking arrangement involving 18,75,000 equity shares. The transaction was completed on March 24, 2026, with Vistra ITCL acting in its capacity as Debenture Trustee/Security Trustee, marking its initial investment in the company through the encumbrance route.
03Mar 26
Innova Captab Limited Schedules Analyst Meeting at Investec Conference on March 9, 2026
Innova Captab Limited has scheduled an analyst and investor meeting for March 9, 2026, at the Investec Promoter & Founder Conference 2026 in Mumbai, starting from 10:00 AM IST. The physical meeting will feature both one-on-one and group interactions, with discussions based solely on publicly available information and no unpublished price-sensitive information to be shared.
27Jan 26
Innova Captab Limited Declares Interim Dividend of ₹2 Per Share for FY 2025-26
Innova Captab Limited has declared an interim dividend of ₹2 per equity share (20% of face value) for FY 2025-26, with record date January 30, 2026. The company has issued detailed TDS guidelines under Finance Act 2020 provisions and mandated electronic-only dividend payments per recent SEBI regulations. Shareholders must update bank details and submit relevant TDS documents by the record date.
24Jan 26
Innova Captab Limited Reports Strong Q3 FY26 Results with Revenue Growth
Innova Captab Limited reported strong Q3 FY26 consolidated results with total income of ₹4,519.47 million, up 40.9% from ₹3,207.87 million in Q3 FY25. Net profit after tax increased to ₹421.49 million from ₹342.04 million year-over-year. Nine-month consolidated income reached ₹11,880.72 million versus ₹9,376.00 million in the previous year. The Board approved results on 22 January 2026 following Audit Committee review, with all regulatory compliance requirements fulfilled.
16Jan 26
Innova Captab Limited Schedules Board Meeting for Q3FY26 Results and Interim Dividend Consideration
Innova Captab Limited has scheduled a board meeting for January 23, 2026, to consider Q3FY26 unaudited financial results for the quarter and nine months ended December 31, 2025, and evaluate an interim dividend proposal for FY2025-26. The record date for potential dividend eligibility is set for January 30, 2026, with the trading window closed since January 1, 2026, and reopening 48 hours after results declaration in compliance with SEBI insider trading regulations.
07Nov 25
Innova Captab Targets 25% Revenue Growth with ₹300 Crore Capex Plan Amid Strong Q2 Performance
Innova Captab Limited has announced a growth strategy targeting a 25% revenue increase through CDMO business expansion and entry into regulated markets. The company plans to invest ₹300 crore in capital expenditure for capacity addition and R&D. Q2 FY26 financial results show 19.50% YoY revenue growth to ₹380.40 crore, 8% EBITDA growth to ₹56.10 crore, and PAT of ₹29.70 crore. The company's strategy includes strengthening API production, scaling up formulation exports, expanding oncology portfolio, and enhancing margins through vertical integration and global partnerships. Recent regulatory inspections of facilities in Baddi and Jammu reinforce the company's adherence to global quality standards.
20Oct 25
Innova Captab's Jammu Facility Poised for GMP Compliance Certificate from Ukraine Drug Authority
Innova Captab Limited's manufacturing facility in Jammu has received a recommendation for Good Manufacturing Practice (GMP) compliance certification from the State Service of Ukraine on Medicines and Drugs Control (SMDC). The SMDC, a participating authority under the Pharmaceutical Inspection Co-operation Scheme (PIC/S), completed a successful inspection of the facility located at SIDCO Industrial Complex, Kathua, Jammu & Kashmir. This recommendation enhances Innova Captab's global credibility, potentially facilitating access to regulated markets and affirming the facility's high manufacturing standards.
16Oct 25
Innova Captab Faces ₹15.81 Crore GST Demand Over Excess Input Tax Credit Refund Claims
Innova Captab Limited received a Show Cause cum Demand Notice from CGST Commissionerate, Shimla, for alleged excess refund claims of Input Tax Credit. The notice covers May 2020 to March 2024, demanding ₹15,81,37,255.40 with additional interest and penalties. The company is accused of incorrectly applying for refunds under Rule 89(4) instead of Rule 89(4B) of CGST Rules. Innova Captab denies merit in the notice and plans to submit a defense within 30 days.
07Aug 25
Innova Captab Reports Robust Q1 Results with 19% Revenue Growth
Innova Captab announced robust Q1 financial results, with revenue increasing 19% YoY to ₹351.50 crore. EBITDA grew 28% to ₹56.60 crore, and PAT rose 5% to ₹31.00 crore. The CDMO Services segment revenue reached ₹249.50 crore, up 8% YoY, while Branded Generics revenue surged 59% to ₹102.10 crore. The company's new Jammu facility gained momentum, contributing to overall growth. Management expressed confidence in sustainable growth and long-term value creation.
19May 25
Innova Captab Reports Strong Q4 Performance with Improved EBITDA and Revenue Growth
Innova Captab's Q4 financial results show significant growth. Revenue increased by 19.77% to 3.15 billion ₹, while EBITDA grew by 25.20% to 477.00 million ₹. The EBITDA margin improved by 65 bps to 15.16%. Net profit saw a modest 3.14% increase to 296.00 million ₹. The company's performance indicates strong market demand and improved operational efficiency.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,779.00
(-0.55%)
6,753.00
(+3.56%)
4,472.90
(+1.42%)
1,105.60
(+1.66%)
1,376.50
(-0.82%)
1,268.50
(-0.56%)
2,264.20
(+0.43%)
2,391.00
(+1.43%)
1,449.00
(-0.19%)
1,424.40
(+1.40%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
